Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

By sjmartinez • January 7, 2025

Blauvelt A, Kircik L, Schlesinger T, Pierce E, Burge R, Behling M, Atwater AR, ElMaraghy H, Armstrong A. Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2025 Dec;36(1):2442720. doi: 10.1080/09546634.2024.2442720. Epub 2025 Jan 6. PMID: 39761965.

Tags: atopic dermatitis, Dermatology, Eczema Area and Severity Index, lebrikizumab, Publications, Quality of Life

Trends in MD-PhD representation and match outcomes across competitive specialties, 2007-2024

Zhou AE, Klufas T, Choi E, Kim YW, Kim JJ, Sarfo A, Sloan B, Feng H. Trends in MD-PhD representation and match outcomes across competitive[...]

Ethical Considerations of Cosmetic GLP-1 Receptor Agonist Prescribing in Dermatology

Jonnalagadda A, Lowry WP, Pathak GN, Choi E, Zhou AE, Grant-Kels JM. Ethical Considerations of Cosmetic GLP-1 Receptor Agonist Prescribing in Dermatology. Clin Dermatol. 2026[...]

Epidermotropic Metastatic Prostate Adenocarcinoma With Florid Squamous Transformation/Differentiation and Associated Acantholysis. An Unusual Clinicopathologic Entity

Hoffman SJ, Sadrolashrafi K, Mobini N. Epidermotropic Metastatic Prostate Adenocarcinoma With Florid Squamous Transformation/Differentiation and Associated Acantholysis. An Unusual Clinicopathologic Entity. Case Rep Dermatol Med.[...]